SEOR SBRT-SG stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis

The use of stereotactic body radiation therapy (SBRT) to treat non-spine bone metastases (NSBM) is becoming increasingly common in clinical practice. The clinical advantages of SBRT include good pain control and high local control rates, although only limited data are available. The Spanish Society of Radiation Oncology (SEOR) SBRT group recently convened a task force of experts in the field to address key questions related to SBRT for NSBM, including treatment indications, planning, techniques, and dose fractionation. The task force reviewed the available literature to develop evidence-based recommendations for the safe application of NSBM SBRT and to standardize and optimize SBRT processes. The present document provides a comprehensive analysis of the available data, including ongoing clinical trials and controversies, providing clinically applicable recommendations.

Marcadores moleculares como factores predictivos de fracaso bioquímico en el cáncer de próstata después de tratamiento radical / Molecular markers as predictive factors biochemical failure after radical treatment of prostate cancer

En la actualidad, los nomogramas basados en los factores pronósticos "convencionales", como el grado de Gleason, el estadio tumoral y el PSA al diagnóstico, siguen siendo las mejores herramientas para predecir el pronóstico del cáncer de próstata (CP). Sin embargo, en la última década, se ha producido un notable avance biotecnológico que ha supuesto una fuente esencial para la investigación de nuevos marcadores moleculares de valor pronóstico y predictivo, tanto en tejido como en suero. En esta revisión, se repasarán los principales biomarcadores, tanto convencionales como más noveles, con principal atención a aquellos implicados en la respuesta a los tratamientos (radioterapia, cirugía u hormonoterapia). Aunque todavía no están preparados para su empleo rutinario en la practica clínica, la combinación de estos biomarcadores, con los marcadores tradicionales y las variables terapéuticas, nos permitirá seleccionar a los pacientes para ensayos con nuevas terapias dirigidas que en un futuro no muy lejano sean la base del tratamiento individualizado(AU)

Clinical nomograms based on Gleason grade, tumor stage, and serum PSA are still the best predictors of prostate cancer (PC) outcome. The biotechnological advancements achieved in the last decade represent a remarkable source for new prognostic and predictive tissue and serum molecular biomarkers. In this review, we will summarize conventional PC prognostic biomarkers and focus on novel identified biomarkers for PC early diagnosis and progression that might be used in the future. Although they are not ready for widespread, routine use, there are reasons to believe that future models will combine these markers with traditional pre-treatment and treatment-related variables and will improve our ability to predict outcome and select the optimal treatment(AU)